# PHA 548 – Lecture 02: Nonbenzodiazepine Sedative-Hypnotics  
## iRAT / TRAT Question Bank (MedChem-Focused)

This bank is designed for storage in GitHub and later export to ExamSoft / Canvas.  
Suggested: Q1–Q6 as iRAT; Q1–Q8 as TRAT.

---

### Q1. Non-BZD but Same Site

Zolpidem exerts its hypnotic effects by acting primarily as:

A. A direct GABAA channel agonist at high doses  
B. A positive allosteric modulator at the BZD site with relative α1 subunit preference  
C. An antagonist at orexin (OX1/OX2) receptors  
D. A full agonist at melatonin MT1/MT2 receptors  

**Correct Answer:** B  

**Bloom’s Level:** Understand  
**Intended Use:** iRAT + TRAT  
**Difficulty Target (p):** 0.75  
**Discrimination Target (d):** ≥ 0.30  

**Rationale:**  
Zolpidem is a non-benzodiazepine **BZD-site agonist** on GABAA, with relative selectivity for **α1-containing** receptors, which enhances hypnotic effects.

**Distractor Rationale:**
- A: Confuses with barbiturate-like direct gating.  
- C: Describes orexin antagonists (DORAs).  
- D: Describes melatonin agonists like ramelteon.

---

### Q2. Core Structural Class – Zolpidem

Zolpidem belongs structurally to which class?

A. Imidazopyridine  
B. Cyclopyrrolone  
C. Pyrazolopyrimidine  
D. 1,4-Benzodiazepine  

**Correct Answer:** A  

**Bloom’s Level:** Remember  
**Use:** iRAT  
**p-target:** 0.80  
**d-target:** ≥ 0.25  

**Rationale:**  
Zolpidem is an **imidazopyridine**; this non-BZD scaffold mimics the spatial pharmacophore of benzodiazepines.

**Distractors:**  
B = eszopiclone class; C = zaleplon class; D = classical BZDs.

---

### Q3. Zaleplon – Ultra-Short Duration

Which statement best explains the **ultra-short duration** of zaleplon?

A. It is primarily cleared by direct glucuronidation of a 3-hydroxy group.  
B. It undergoes rapid metabolism by aldehyde oxidase with inactive metabolites.  
C. It has a very long distribution half-life and large volume of distribution.  
D. It is a prodrug converted slowly to an active BZD.  

**Correct Answer:** B  

**Bloom’s Level:** Apply  
**Use:** iRAT + TRAT  
**p-target:** 0.60  
**d-target:** ≥ 0.35  

**Rationale:**  
Zaleplon’s **brief t½ (~1 h)** is driven by **rapid aldehyde oxidase and CYP3A4 metabolism** to inactive metabolites, resulting in minimal accumulation.

**Distractor Rationale:**  
- A: Confuses with 3-OH BZDs (temazepam, oxazepam, lorazepam).  
- C: Would prolong, not shorten, duration.  
- D: Zaleplon is not a prodrug.

---

### Q4. Eszopiclone vs Zolpidem – Duration

Compared to zolpidem, eszopiclone generally has:

A. Shorter half-life due to ester hydrolysis by esterases  
B. Similar half-life but more active metabolites  
C. Longer half-life due to somewhat greater polarity and different metabolic profile  
D. Longer half-life because it is converted to diazepam as an active metabolite  

**Correct Answer:** C  

**Bloom’s Level:** Analyze  
**Use:** iRAT + TRAT  
**p-target:** 0.55–0.65  
**d-target:** ≥ 0.35  

**Rationale:**  
Eszopiclone (cyclopyrrolone) has a **longer t½ (~5–7 h)** than zolpidem, allowing both **sleep onset and some sleep maintenance**; it is not a prodrug for diazepam.

**Distractors:**  
A = remimazolam-like description; B = oversimplification; D = incorrect prodrug relationship.

---

### Q5. Z-Drug Pharmacophore vs Benzodiazepines

The main **medicinal chemistry** difference between Z-drugs and classical benzodiazepines is:

A. Z-drugs lack any aromatic ring, while BZDs contain at least one.  
B. Z-drugs use non-benzodiazepine heteroaromatic scaffolds to mimic BZD-site pharmacophore geometry.  
C. Z-drugs bind only at α2/α3 GABAA receptors, while BZDs are α1-selective.  
D. Z-drugs act as inverse agonists at the BZD site, while BZDs are agonists.  

**Correct Answer:** B  

**Bloom’s Level:** Understand / Analyze  
**Use:** iRAT + TRAT  
**p-target:** 0.70  
**d-target:** ≥ 0.30  

**Rationale:**  
Zolpidem, zaleplon, eszopiclone use **heteroaromatic cores** (imidazopyridine, pyrazolopyrimidine, cyclopyrrolone) to achieve the necessary spatial arrangement without the diazepine ring.

**Distractors:**  
A = false; they all maintain aromaticity.  
C = reversed; Z-drugs are more α1-biased.  
D = incorrect: they are agonists/positive modulators, not inverse agonists.

---

### Q6. Active Metabolite Risk – MedChem Pattern

Which structural/PK pattern is most associated with **minimal active metabolite formation** among the non-BZD hypnotics?

A. Highly lipophilic, bulky aryl groups and N-alkyl chains  
B. Short, heteroaromatic scaffold with rapid oxidative clearance  
C. Barbituric acid core with sulfur substitution at C2  
D. 3-hydroxy substitution on a benzodiazepine ring system  

**Correct Answer:** B  

**Bloom’s Level:** Analyze  
**Use:** iRAT + TRAT  
**p-target:** 0.55–0.65  
**d-target:** ≥ 0.35  

**Rationale:**  
Z-drugs like zolpidem and zaleplon are designed as **short, heteroaromatic scaffolds** that undergo rapid metabolism to **inactive** metabolites.

**Distractors:**  
A = describes many long-acting BZDs.  
C = thiobarbiturates.  
D = 3-OH BZDs (temazepam) → shortish duration but still BZD, not Z-drug.

---

### Q7. Patient Case – Early Morning Driving

A 40-year-old patient has difficulty **initiating sleep** but must drive at 6 AM. Which non-BZD hypnotic is most appropriate to minimize next-morning psychomotor impairment?

A. Eszopiclone at bedtime  
B. Zaleplon at bedtime  
C. Diazepam at bedtime  
D. Flurazepam at bedtime  

**Correct Answer:** B  

**Bloom’s Level:** Apply/Evaluate  
**Use:** TRAT (team discussion)  
**p-target:** 0.55  
**d-target:** ≥ 0.35  

**Rationale:**  
**Zaleplon** has the shortest half-life (~1 h), minimizing morning carry-over.

**Distractors:**  
A = longer t½; may leave residual sedation.  
C/D = long-acting BZDs with active metabolites.

---

### Q8. Complex Sleep Behaviors — Structural Insight

Complex sleep behaviors (sleep-driving, sleep-eating) have been reported most prominently with:

A. Ramelteon  
B. Zolpidem  
C. Daridorexant  
D. Buspirone  

**Correct Answer:** B  

**Bloom’s Level:** Understand / Apply  
**Use:** TRAT  
**p-target:** 0.60–0.70  
**d-target:** ≥ 0.30  

**Rationale:**  
Zolpidem, due to its **potent α1-preferring GABAA modulation**, is strongly linked to complex sleep behaviors.

**Distractors:**  
A = melatonin agonist; limited such reports.  
C = orexin antagonist; main AE is somnolence.  
D = anxiolytic with minimal sedation.

---

## Suggested Usage

- **iRAT:** Q1–Q6  
- **TRAT:** Q1–Q8 (with discussion prompts)  

You can later convert this bank to JSON/CSV using the same structure as Lecture 1 for ExamSoft/Canvas import.
